{"title": "Los efectos del uso de corticosteroides t\u00f3picos sobre la sensibilidad a la insulina y el recambio \u00f3seo", "author": "Jacob Thyssen", "url": "https://ichgcp.net/es/clinical-trials-registry/NCT04114097", "hostname": "ichgcp.net", "description": "Los investigadores creen que la evidencia epidemiol\u00f3gica emergente que relaciona el uso t\u00f3pico de corticosteroides con el desarrollo de diabetes tipo 2 y osteop.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2019-10-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Los efectos del uso de corticosteroides t\u00f3picos sobre la sensibilidad a la insulina y el recambio \u00f3seo\n27 de abril de 2021 actualizado por:\n[Jacob Thyssen](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jacob%20Thyssen)\nLos investigadores creen que la evidencia epidemiol\u00f3gica emergente que relaciona el uso t\u00f3pico de corticosteroides con el desarrollo de diabetes tipo 2 y osteoporosis apunta a problemas potencialmente masivos, aunque cl\u00ednicamente no reconocidos, asociados con el tratamiento con corticosteroides t\u00f3picos. Usando una metodolog\u00eda de vanguardia, el presente estudio delinear\u00e1 el impacto del uso de corticosteroides t\u00f3picos en la sensibilidad a la insulina y los marcadores de recambio \u00f3seo en pacientes con dermatitis at\u00f3pica y, por lo tanto, proporcionar\u00e1 datos importantes que pueden tener implicaciones para millones de personas que usan corticosteroides t\u00f3picos. corticosteroides\nDescripci\u00f3n general del estudio\nEstado\nTerminado\nCondiciones\nTipo de estudio\nIntervencionista\nInscripci\u00f3n (Actual)\n36\nFase\n- Fase 4\nContactos y Ubicaciones\nEsta secci\u00f3n proporciona los datos de contacto de quienes realizan el estudio e informaci\u00f3n sobre d\u00f3nde se lleva a cabo este estudio.\nUbicaciones de estudio\n-\nDinamarca\n-\nRegion Hovedstaden\n-\nHellerup, Region Hovedstaden, Dinamarca, 2900\n- Department of Dermatology and Allergy\n-\n-\nCriterios de participaci\u00f3n\nLos investigadores buscan personas que se ajusten a una determinada descripci\u00f3n, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.\nCriterio de elegibilidad\nEdades elegibles para estudiar\n18 a\u00f1os a 75 a\u00f1os (Adulto, Adulto Mayor)\nAcepta Voluntarios Saludables\nNo\nG\u00e9neros elegibles para el estudio\nTodos\nDescripci\u00f3n\nCriterios de inclusi\u00f3n\n- Edad 18-75 a\u00f1os\n- DA seg\u00fan los Criterios de Hanifin y Rajka24\n- AD durante al menos 3 a\u00f1os\n- IMC \u2264 30 kg/m2\n- Hemoglobina A1c (HbA1c) \u2264 42 mmol/mol (6,0 %)\n- Hemoglobina normal (hombres: 8,3-10,5 mmol/L y mujeres 7,3-9,5 mmol/L. Se permitir\u00e1 una desviaci\u00f3n del 5% si el paciente adem\u00e1s de este est\u00e1 sano)\n- Consentimiento informado\n- En general, no se debe diagnosticar a los pacientes con enfermedades que puedan afectar o verse afectadas por el estudio/tratamiento (evaluado por un m\u00e9dico) (como infecciones de la piel no tratadas, acn\u00e9 vulgar (al lado de la regi\u00f3n de la cara), un defecto de la barrera cut\u00e1nea, como el s\u00edndrome de Netherton , ictiosis lamelar, eritrodermia generalizada o enfermedad de injerto contra hu\u00e9sped cut\u00e1nea, inmunodeficiencias cong\u00e9nitas o adquiridas o en pacientes en terapia que causan inmunosupresi\u00f3n, y Protopic pomada no debe aplicarse a lesiones que se consideran potencialmente malignas o premalignas. Otros pacientes no deben sufrir enfermedad/insuficiencia renal o hep\u00e1tica. Consulte el SPC de Protopic y Betnovate).\nCriterio de exclusi\u00f3n\n- Diabetes mellitus diagnosticada\n- Otras enfermedades inflamatorias cr\u00f3nicas (incluidas, entre otras, la artritis reumatoide, la enfermedad inflamatoria intestinal, etc.) adem\u00e1s de la EA y la rinitis o el asma que no requieren tratamiento (tratados en las \u00faltimas 4 semanas)\n- Embarazo (se realizar\u00e1 una prueba de orina en cada visita y se requiere control de la natalidad, ver m\u00e1s abajo*)\n- lactancia materna\n- Tratamiento con medicamentos que pueden afectar el metabolismo de la glucosa adem\u00e1s de TCS dentro de un mes antes del proyecto\n- Fumador diario, alcoh\u00f3lico o drogadicto\n- Hipersensibilidad a Protopic o Betnovate\nPlan de estudios\nEsta secci\u00f3n proporciona detalles del plan de estudio, incluido c\u00f3mo est\u00e1 dise\u00f1ado el estudio y qu\u00e9 mide el estudio.\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Otro\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: Cuadruplicar\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nExperimental: Betametasona-17-valerato + pomada de placebo\nPacientes con dermatitis at\u00f3pica: tratamiento t\u00f3pico con pomada de cuerpo completo dos veces al d\u00eda que contiene corticosteroides (\"Betnovate\", pomada de dipropionato de betametasona al 0,1%) y placebo\n|\n|\nExplore los efectos sist\u00e9micos de Betnovate\n|\n|\nComparador activo: Pomada de tacrolim\u00fas\nPacientes con dermatitis at\u00f3pica: tratamiento t\u00f3pico con pomada de cuerpo completo dos veces al d\u00eda que contiene inhibidor de calcineurina (\"Protopic\", pomada de tacrolimus al 0,1%)\n|\n|\nCompare los efectos sist\u00e9micos de Betnovate con Protopic\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nCambio en la sensibilidad a la insulina de todo el cuerpo\nPeriodo de tiempo: L\u00ednea de base, despu\u00e9s de 14 d\u00edas de tratamiento diario y despu\u00e9s de 4 semanas de tratamiento dos veces al d\u00eda dos veces por semana\n|\n|\nCambio en la sensibilidad a la insulina de todo el cuerpo durante el tratamiento con corticosteroides t\u00f3picos en comparaci\u00f3n con el grupo de control tratado con inhibidores de la calcineurina t\u00f3picos. La sensibilidad a la insulina se evaluar\u00e1 mediante el m\u00e9todo de pinzamiento eugluc\u00e9mico hiperinsulin\u00e9mico con trazador de glucosa y glicerol y calorimetr\u00eda indirecta (tasa de desaparici\u00f3n (Rd)).\n|\n|\nL\u00ednea de base, despu\u00e9s de 14 d\u00edas de tratamiento diario y despu\u00e9s de 4 semanas de tratamiento dos veces al d\u00eda dos veces por semana\nColaboradores e Investigadores\nAqu\u00ed es donde encontrar\u00e1 personas y organizaciones involucradas en este estudio.\nPatrocinador\nColaboradores\nInvestigadores\n- Investigador principal: Jacob P Thyssen, Professor, MD, DMSc, Department of Dermatology and Allergy, Gentofte Hospital, Denmark\nFechas de registro del estudio\nEstas fechas rastrean el progreso del registro del estudio y los env\u00edos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los est\u00e1ndares de control de calidad espec\u00edficos antes de publicarlos en el sitio web p\u00fablico.\nFechas importantes del estudio\nInicio del estudio (Actual)\n22 de agosto de 2019\nFinalizaci\u00f3n primaria (Actual)\n15 de marzo de 2021\nFinalizaci\u00f3n del estudio (Actual)\n15 de marzo de 2021\nFechas de registro del estudio\nEnviado por primera vez\n1 de octubre de 2019\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\n2 de octubre de 2019\nPublicado por primera vez (Actual)\n3 de octubre de 2019\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n28 de abril de 2021\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n27 de abril de 2021\n\u00daltima verificaci\u00f3n\n1 de abril de 2021\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\n-\n[Trastornos del metabolismo de la glucosa](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Glucose%20Metabolism%20Disorders)\n-\n[Enfermedades metab\u00f3licas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Metabolic%20Diseases)\n-\n[Enfermedades de la piel](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases)\n-\n[Enfermedades del sistema inmunol\u00f3gico](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases)\n-\n[Hipersensibilidad, Inmediata](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypersensitivity%2C%20Immediate)\n-\n[Enfermedades Gen\u00e9ticas Cong\u00e9nitas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Genetic%20Diseases%2C%20Inborn)\n-\n[Enfermedades De La Piel Gen\u00e9ticas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases%2C%20Genetic)\n-\n[Hiperinsulinismo](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hyperinsulinism)\n-\n[Hipersensibilidad](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypersensitivity)\n-\n[Enfermedades De La Piel Eccematosas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases%2C%20Eczematous)\n-\n[Dermatitis](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dermatitis)\n-\n[Resistencia a la insulina](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Insulin%20Resistance)\n-\n[Dermatitis At\u00f3pica](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dermatitis%2C%20Atopic)\n-\n[Efectos fisiol\u00f3gicos de las drogas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs)\n-\n[Mecanismos moleculares de acci\u00f3n farmacol\u00f3gica](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action)\n-\n[Inhibidores de enzimas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors)\n-\n[Agentes antiinflamatorios](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Inflammatory%20Agents)\n-\n[Agentes inmunosupresores](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunosuppressive%20Agents)\n-\n[Factores inmunol\u00f3gicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors)\n-\n[Glucocorticoides](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Glucocorticoids)\n-\n[Hormonas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Hormones)\n-\n[Hormonas, sustitutos hormonales y antagonistas hormonales](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Hormones%2C%20Hormone%20Substitutes%2C%20and%20Hormone%20Antagonists)\n-\n[Agentes antiasm\u00e1ticos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Asthmatic%20Agents)\n-\n[Agentes del sistema respiratorio](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Respiratory%20System%20Agents)\n-\n[Inhibidores de calcineurina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Calcineurin%20Inhibitors)\n-\n[Betametasona](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone)\n-\n[Valerato de betametasona](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone%20Valerate)\n-\n[Betametasona-17,21-dipropionato](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone-17%2C21-dipropionate)\n-\n[Benzoato de betametasona](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone%20benzoate)\n-\n[Fosfato de sodio de betametasona](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone%20sodium%20phosphate)\n-\n[Tacrolimus](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Tacrolimus)\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- H-18064175\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nNo\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nNo\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Dermatitis at\u00f3pica\n-\nNCT06039241Reclutamiento\n-\nNCT06035354Reclutamiento\n-\nNCT06032403Reclutamiento\n-\nNCT06024499A\u00fan no reclutandoDermatitis at\u00f3pica | Dermatitis at\u00f3pica Eccema | Dermatitis at\u00f3pica del cuero cabelludo\n-\nNCT06022874Reclutamiento\n-\nNCT06015308A\u00fan no reclutando\n-\nNCT06012812A\u00fan no reclutando\n[Un estudio para ampliar la eficacia y seguridad de la inyecci\u00f3n de SHR-1819 en pacientes adultos con dermatitis at\u00f3pica de moderada a grave](https://ichgcp.net/es/clinical-trials-registry/NCT06012812)Dermatitis at\u00f3pica moderada a severa\n-\nNCT06011629ReclutamientoDermatitis al\u00e9rgica de contacto | Reacci\u00f3n cut\u00e1nea adversa\n-\nNCT06009094A\u00fan no reclutando\n-\nNCT06005792Reclutamiento", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT04114097", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT04114097&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT04114097", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jacob%20Thyssen", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Atopic%20Dermatitis", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Atopic%20Eczema", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betnovate%2C%20betamethasone%20dipropionate%20ointment%200.1%25%20and%20placebo", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Protopic%2C%20tacrolimus%20ointment%200.1%25", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betnovate%2C%20betamethasone%20dipropionate%20ointment%200.1%25%20and%20placebo", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Protopic%2C%20tacrolimus%20ointment%200.1%25", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jacob%20Thyssen", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=LEO%20Pharma", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=topical%20corticosteroids", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=topical%20calcineurin%20inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Glucose%20Metabolism%20Disorders", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Metabolic%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypersensitivity%2C%20Immediate", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Genetic%20Diseases%2C%20Inborn", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases%2C%20Genetic", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hyperinsulinism", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypersensitivity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases%2C%20Eczematous", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dermatitis", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Insulin%20Resistance", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dermatitis%2C%20Atopic", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Inflammatory%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunosuppressive%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Glucocorticoids", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Hormones", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Hormones%2C%20Hormone%20Substitutes%2C%20and%20Hormone%20Antagonists", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Asthmatic%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Respiratory%20System%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Calcineurin%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone%20Valerate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone-17%2C21-dipropionate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone%20benzoate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Betamethasone%20sodium%20phosphate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Tacrolimus", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06039241", "https://ichgcp.net/es/clinical-trials-registry/NCT06035354", "https://ichgcp.net/es/clinical-trials-registry/NCT06032403", "https://ichgcp.net/es/clinical-trials-registry/NCT06024499", "https://ichgcp.net/es/clinical-trials-registry/NCT06022874", "https://ichgcp.net/es/clinical-trials-registry/NCT06015308", "https://ichgcp.net/es/clinical-trials-registry/NCT06012812", "https://ichgcp.net/es/clinical-trials-registry/NCT06011629", "https://ichgcp.net/es/clinical-trials-registry/NCT06009094", "https://ichgcp.net/es/clinical-trials-registry/NCT06005792", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/azerbaijan", "https://ichgcp.net/es/cro-list/country/bahrain", "https://ichgcp.net/es/cro-list/country/bangladesh", "https://ichgcp.net/es/cro-list/country/congo", "https://ichgcp.net/es/cro-list/country/ethiopia", "https://ichgcp.net/es/cro-list/country/france", "https://ichgcp.net/es/cro-list/country/kenya", "https://ichgcp.net/es/cro-list/country/mali", "https://ichgcp.net/es/cro-list/country/malta", "https://ichgcp.net/es/cro-list/country/norway", "https://ichgcp.net/es/cro-list/country/saudi_arabia", "https://ichgcp.net/es/cro-list/country/trinidad_tobago", "https://ichgcp.net/es/cro-list/country/venezuela", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/lithuania/company/sgs", "https://ichgcp.net/es/cro-list/country/lithuania/company/psi", "https://ichgcp.net/es/cro-list/country/lithuania/company/biomapas", "https://ichgcp.net/es/cro-list/country/lithuania/company/sanaclis", "https://ichgcp.net/es/cro-list/country/lithuania/company/dokumeds", "https://ichgcp.net/es/cro-list/country/lithuania/company/parexel", "https://ichgcp.net/es/cro-list/country/lithuania/company/comac_medical", "https://ichgcp.net/es/cro-list/country/lithuania/company/gct_global_clinical_trials", "https://ichgcp.net/es/cro-list/country/lithuania/company/medfiles", "https://ichgcp.net/es/cro-list/country/lithuania", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT04114097", "https://ichgcp.net/de/clinical-trials-registry/NCT04114097", "https://ichgcp.net/clinical-trials-registry/NCT04114097", "https://ichgcp.net/es/clinical-trials-registry/NCT04114097", "https://ichgcp.net/fr/clinical-trials-registry/NCT04114097", "https://ichgcp.net/it/clinical-trials-registry/NCT04114097", "https://ichgcp.net/hu/clinical-trials-registry/NCT04114097", "https://ichgcp.net/nl/clinical-trials-registry/NCT04114097", "https://ichgcp.net/no/clinical-trials-registry/NCT04114097", "https://ichgcp.net/pl/clinical-trials-registry/NCT04114097", "https://ichgcp.net/pt/clinical-trials-registry/NCT04114097", "https://ichgcp.net/fi/clinical-trials-registry/NCT04114097", "https://ichgcp.net/sv/clinical-trials-registry/NCT04114097", "https://ichgcp.net/cs/clinical-trials-registry/NCT04114097", "https://ichgcp.net/ru/clinical-trials-registry/NCT04114097", "https://ichgcp.net/ja/clinical-trials-registry/NCT04114097", "https://ichgcp.net/zh/clinical-trials-registry/NCT04114097", "https://ichgcp.net/ko/clinical-trials-registry/NCT04114097", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}